Live Breaking News & Updates on Retinal Cell

Stay updated with breaking news from Retinal cell. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

OpRegen® (RG6501) Phase 1/2a Clinical Study 24-Month Visual Acuity Results Featured at 2024 Retinal Cell & Gene Therapy Innovation Summit

BCVA gains of +5.5 letters at 24 months in Cohort 4 patients

BCVA gains of +7.4 letters among Cohort 4 patients with extensive OpRegen bleb coverage of the GA lesion

Maintenance or increases. ....

Israel General , United States , David Telander , Brianm Culley , Roche Group , Foundation Fighting Blindness , Exchange Commission , Oregon Health Science University Casey Eye Institute , Retinal Consultants Medical Group , Eterna Therapeutics Inc , Lineage Cell Therapeutics Inc , Lineage Cell Therapeutics , Gene Therapy Innovation , Oregon Health , Science University Casey Eye , Retinal Pigment Epithelium , Cell Therapy , Geographic Atrophy , Early Treatment Diabetic Retinopathy Study , Retinal Cell , Gene Therapy Innovation Summit , Opregen Phase , Cell Therapeutics , Eterna Therapeutics , Annual Report ,

Ocugen Announces OCU400—Modifier Gene Therapy—Phase 1/2 Data Presentation at Retinal Cell and Gene Therapy Innovation Summit 2024

MALVERN, Pa., April 29, 2024 Ocugen, Inc. , a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines, today announced that. ....

United States , University Of Arizona , Benjamin Bakall , Ocugen Inc , Exchange Commission , Clinical Research At Associated Retina Consultants , Head Of Communications , Oregon Health , Nuclear Hormone Receptor , College Of Medicine , Science University Casey Eye Institute , Foundation Fighting Blindness , Clinical Research , Associated Retina Consultants , Clinical Assistant Professor , Retinal Cell , Gene Therapy Innovation Summit , Science University Casey Eye , Hormone Receptor Based Gene Modifier Therapy , Hyatt Regency , Private Securities Litigation Reform Act ,

RG6501 (OpRegen®) Phase 1/2a Clinical Study 24 Month Results to Be Featured at 2024 Retinal Cell & Gene Therapy Innovation Summit

Lineage Cell Therapeutics, Inc. , a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that 24 month results from patients enrolled in. ....

United States , David Telander , Lineage Cell Therapeutics Inc , Casey Eye Institute , Retinal Consultants Medical Group , Exchange Commission , Eterna Therapeutics Inc , Oregon Health Science University Casey Eye Institute , Roche Group , Foundation Fighting Blindness , Lineage Cell Therapeutics , Gene Therapy Innovation , Hyatt Regency Seattle , Oregon Health , Science University Casey Eye , Retinal Pigment Epithelium , Cell Therapy , Geographic Atrophy , Retinal Cell , Gene Therapy Innovation Summit , Foundation Fighting , Eye Institute , Pacific Northwest , Opregen Phase , Cell Therapeutics , Eterna Therapeutics ,

A Promising New Approach For Glaucoma

Recent medical breakthroughs in RGC (retinal ganglion cell) replacement therapy offer hope for those suffering from glaucoma. ....

Retinal Ganglion , Ganglion Cells , Retinal Cell , Making Retinal Ganglion Cells , Treatment For Glaucoma , Glaucoma Treatments , Retinal Cell Therapy , Retinal Ganglion Cells , Retinal Cell Replacements , Cell Therapy , Cell Therapy For Glaucoma ,

Ascidian Therapeutics to Present Data From Its Lead Program Targeting ABCA4 Retinopathies at the Retinal Cell and Gene Therapy Innovation Summit and ARVO 2023 Annual Meeting

/PRNewswire/ Ascidian Therapeutics, a biotechnology company focused on treating human diseases by rewriting RNA, announced today that Chief Medical Officer. ....

United States , Jay Barth , Shimyn Slomovic , Romesh Subramanian , Orleans Ernestn Morial Convention Center , Foundation Fighting Blindness , Oregon Health Science University , Casey Eye Institute , Association For Research , Chief Medical Officer Jay Barth , Eighth Annual Retinal Cell , Gene Therapy Innovation Summit , Molecular Biology Shimyn Slomovic , Retinal Cell , Chief Executive Officer , Oregon Health , Science University , Friday April , Marriott New Orleans Warehouse Arts District , New Orleans , Presentation Number , New Orleans Ernest , Convention Center , Ascidian Therapeutics , Health Care Amp Hospitals , Medical Pharmaceuticals ,